Seres Therapeutics Inc (MCRB)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Roger J. Pomerantz
Employees:
145
200 SIDNEY STREET, CAMBRIDGE, MA 02139
617 945 9626

Seres Therapeutics, Inc. is a microbiome therapeutics platform company, which engages in developing biological drugs. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Data derived from most recent annual or quarterly report
Market Cap 311.009 Million Shares Outstanding92.014 Million Avg 30-day Volume 1.545 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.92
Price to Revenue0.0 Debt to Equity0.623 EBITDA-77.357 Million
Price to Book Value0.0 Operating Margin-60.353100000000005 Enterprise Value0
Current Ratio3.196 EPS Growth0.143 Quick Ratio3.011
1 Yr BETA 1.49 52-week High/Low 25.06 / 2.5 Profit Margin-61.6459
Operating Cash Flow Growth69.3885 Altman Z-Score0.0 Free Cash Flow to Firm -46.467 Million
Earnings Report2022-08-02
View SEC Filings from MCRB instead.

View recent insider trading info

Funds Holding MCRB (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MCRB BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-06-24:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-06-07:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-06:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-01:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-07-22:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-07-01:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2021-06-21:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    DERE WILLARD H

    • Director
    35,000 2022-06-22 1

    KENDER RICHARD N

    • Director
    35,000 2022-06-22 2

    AUSIELLO DENNIS A

    • Director
    35,000 2022-06-22 1

    GRAVES KURT

    • Director
    35,000 2022-06-22 2

    BEHAR GREGORY

    • Director
    35,000 2022-06-22 1

    ZAUSNER MERYL

    • Director
    35,000 2022-06-22 2

    BIONDI PAUL

    • Director
    35,000 2022-06-22 1

    BERENSON STEPHEN

    • Director
    35,000 2022-06-22 1

    CLOGHESSY PAULA SEE REMARKS

    • Officer
    0 2022-02-07 2

    ARKOWITZ DAVID SEE REMARKS

    • Officer
    190,000 2022-02-04 1

    DESROSIER THOMAS CHIEF LEGAL OFFICER AND EVP

    • Officer
    130,000 2022-02-04 1

    SHAFF ERIC D. PRESIDENT, CEO

    • Officer
    • Director
    500,000 2022-02-04 1

    HENN MATTHEW R. SEE REMARKS

    • Officer
    175,000 2022-02-04 1

    VON MOLTKE LISA SEE REMARKS

    • Officer
    175,000 2022-02-04 1

    YOUNG TERESA L. SEE REMARKS

    • Officer
    120,000 2022-02-04 1

    EGE DAVID S. SEE REMARKS

    • Officer
    175,000 2022-02-04 1

    NUTRITIONAL HEALTH LTP FUND GENERAL PARTNER LLC

    NUTRITIONAL HEALTH LTP FUND, L.P.

    AFEYAN NOUBAR

    • 10% Owner
    14,754,820 2021-05-17 0

    CHAPMAN MARCUS SEE REMARKS

    • Officer
    0 2021-02-04 0

    FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC

    FLAGSHIP VENTURES FUND IV, L.P.

    FLAGSHIP VENTURES FUND IV-RX, L.P.

    NUTRITIONAL HEALTH LTP FUND GENERAL PARTNER LLC

    NUTRITIONAL HEALTH LTP FUND, L.P.

    FLAGSHIP PIONEERING INC.

    FLAGSHIP PIONEERING FUND VI GENERAL PARTNER LLC

    FLAGSHIP PIONEERING FUND VI, L.P.

    AFEYAN NOUBAR

    • 10% Owner
    15,049,991 2020-11-23 0

    AUNINS JOHN G. CHIEF TECHNOLOGY OFFICER & EVP

    • Officer
    0 2020-01-29 0

    AFEYAN NOUBAR

    • Director
    • 10% Owner
    21,586,905 2019-06-18 0

    FLAGSHIP PIONEERING INC.

    FLAGSHIP PIONEERING FUND VI GENERAL PARTNER LLC

    FLAGSHIP PIONEERING FUND VI, L.P.

    NUTRITIONAL HEALTH LTP FUND GENERAL PARTNER LLC

    NUTRITIONAL HEALTH LTP FUND, L.P.

    • 10% Owner
    4,444,444 2019-06-18 0

    POMERANTZ ROGER

    • Director
    0 2019-06-13 0

    KIM LORENCE H.

    • Director
    0 2019-06-13 0

    COOK DAVID N SEE REMARKS

    • Officer
    147,435 2019-01-26 0

    HORGAN KEVIN CHIEF MEDICAL OFFICER AND EVP

    • Officer
    0 2019-01-25 0

    TRUCKSIS MICHELE SEE REMARKS

    • Officer
    4,893 2018-01-26 0

    HASHAD WAEL EVP & CHIEF COMMERCIAL OFFICER

    • Officer
    0 2017-01-26 0

    HUTT PETER BARTON

    • Director
    0 2016-06-15 0

    AFEYAN NOUBAR

    FLAGSHIP VENTURES FUND 2007, L.P.

    FLAGSHIP VENTURES FUND IV, L.P.

    FLAGSHIP VENTURES FUND IV-RX, L.P.

    FLAGSHIP VENTURELABS IV, LLC

    FLAGSHIP VENTURES 2007 GENERAL PARTNER LLC

    FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC

    KANIA EDWIN M JR

    • Director
    • 10% Owner
    14,641,852 2016-05-25 0

    NESTLE HEALTH SCIENCE US HOLDINGS, INC.

    NESTLE SA

    NIMCO US, INC.

    • 10% Owner
    6,888,888 2015-07-01 0

    AFEYAN NOUBAR

    FLAGSHIP VENTURES FUND 2007, L.P.

    FLAGSHIP VENTURES FUND IV, L.P.

    FLAGSHIP VENTURES FUND IV-RX, L.P.

    FLAGSHIP VENTURES 2007 GENERAL PARTNER LLC

    FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC

    KANIA EDWIN M JR

    • Director
    • 10% Owner
    14,682,876 2015-06-25 0

    CAUTREELS WERNER

    • Director
    0 2015-06-25 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    DERE WILLARD H - Director

    2022-06-24 16:30:14 -0400 2022-06-22 A 35,000 a 35,000 direct

    ZAUSNER MERYL - Director

    2022-06-24 16:32:18 -0400 2022-06-22 A 35,000 a 35,000 direct

    KENDER RICHARD N - Director

    2022-06-24 16:32:07 -0400 2022-06-22 A 35,000 a 35,000 direct

    GRAVES KURT - Director

    2022-06-24 16:32:03 -0400 2022-06-22 A 35,000 a 35,000 direct

    BERENSON STEPHEN - Director

    2022-06-24 16:30:29 -0400 2022-06-22 A 35,000 a 35,000 direct

    KENDER RICHARD N - Director

    2022-06-24 16:36:03 -0400 2022-06-22 A 35,000 a 35,000 direct

    ZAUSNER MERYL - Director

    2022-06-24 16:35:37 -0400 2022-06-22 A 35,000 a 35,000 direct

    GRAVES KURT - Director

    2022-06-24 16:35:31 -0400 2022-06-22 A 35,000 a 35,000 direct

    BIONDI PAUL - Director

    2022-06-24 16:35:10 -0400 2022-06-22 A 35,000 a 35,000 direct

    BEHAR GREGORY - Director

    2022-06-24 16:31:17 -0400 2022-06-22 A 35,000 a 35,000 direct

    AUSIELLO DENNIS A - Director

    2022-06-24 16:31:03 -0400 2022-06-22 A 35,000 a 35,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    SERES THERAPEUTICS INC MCRB 2022-06-24 22:15:03 UTC 0.9917 0.5783 600000
    SERES THERAPEUTICS INC MCRB 2022-06-24 21:45:03 UTC 0.9917 0.5783 600000
    SERES THERAPEUTICS INC MCRB 2022-06-24 21:15:04 UTC 0.9917 0.5783 600000
    SERES THERAPEUTICS INC MCRB 2022-06-24 20:45:03 UTC 0.9917 0.5783 600000
    SERES THERAPEUTICS INC MCRB 2022-06-24 20:15:03 UTC 0.9917 0.5783 600000
    SERES THERAPEUTICS INC MCRB 2022-06-24 19:45:03 UTC 0.9917 0.5783 600000
    SERES THERAPEUTICS INC MCRB 2022-06-24 19:15:03 UTC 0.9917 0.5783 600000
    SERES THERAPEUTICS INC MCRB 2022-06-24 18:45:03 UTC 0.9917 0.5783 600000
    SERES THERAPEUTICS INC MCRB 2022-06-24 18:15:04 UTC 0.9917 0.5783 600000
    SERES THERAPEUTICS INC MCRB 2022-06-24 17:45:03 UTC 0.9917 0.5783 600000
    SERES THERAPEUTICS INC MCRB 2022-06-24 17:15:03 UTC 0.9917 0.5783 600000
    SERES THERAPEUTICS INC MCRB 2022-06-24 16:45:03 UTC 1.0731 0.4969 650000
    SERES THERAPEUTICS INC MCRB 2022-06-24 16:15:03 UTC 1.0731 0.4969 650000
    SERES THERAPEUTICS INC MCRB 2022-06-24 15:45:03 UTC 1.0731 0.4969 600000
    SERES THERAPEUTICS INC MCRB 2022-06-24 15:15:03 UTC 1.0731 0.4969 600000
    SERES THERAPEUTICS INC MCRB 2022-06-24 14:45:03 UTC 1.1607 0.4093 600000
    SERES THERAPEUTICS INC MCRB 2022-06-24 14:15:03 UTC 1.1607 0.4093 600000
    SERES THERAPEUTICS INC MCRB 2022-06-24 13:45:03 UTC 1.1607 0.4093 600000
    SERES THERAPEUTICS INC MCRB 2022-06-24 13:15:03 UTC 1.1607 0.4093 600000
    SERES THERAPEUTICS INC MCRB 2022-06-24 12:45:03 UTC 1.1607 0.4093 600000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    RUSSELL INVESTMENT CO- U.S. Dynamic Equity Fund MCRB -3489.0 shares, $-82863.75 2021-01-31 N-PORT

    Elevate your investments